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One of the main concerns in human milk banks (HMB) is the transmission of human
cytomegalovirus (HCMV) that could be present in the milk of infected women. There are
consistent data showing that this virus is destroyed by Holder pasteurization (62.5◦C for
30min), but there is a lack of information about the response of the virus to the treatment
at lower temperatures in strict HMB conditions. In order to analyze the effectiveness of
different temperatures of pasteurization to eliminate HCMV in human milk, a preliminary
assay was performed incubating HCMV-spiked raw milk samples from donor mothers
at tested temperatures in a PCR thermocycler and the viral infectivity was assayed on
cell cultures. No signs of viral replication were observed after treatments at temperatures
equal or >53◦C for 30, 20, and 10min, 58◦C for 5min, 59◦C for 2min, and 60◦C for
1min. These data were confirmed in a pasteurizer-like model introducing HCMV-spiked
milk in disposable baby bottles. No viral infectivity was detected on cell cultures after
heating treatment of milk for 30min at temperatures from 56 to 60◦C. Thus, our results
show that by using conventional pasteurization conditions, temperatures in the range
of 56–60◦C are enough to inactivate HCMV. Consequently, we consider that, in order to
provide a higher quality product, the current recommendation to pasteurize bothmother’s
own milk and donated milk at 62.5◦C must be re-evaluated.
Keywords: holder pasteurization, donor human milk, viral inactivation, human milk bank, breast milk,
cytomegalovirus
INTRODUCTION
It is widely accepted that breast milk is the optimal source of nutrition for infants (1, 2). However,
it has been reported that only 27% of mothers were able to provide sufficient milk to their preterm
infants (3). In this situation, the preferred alternative is donated human milk, and only if this is not
available, preterm formula (2).
As any other Substance of Human Origin (SOHO), human milk has a potential risk of
infectious disease transmission. In order to minimize this risk, several strategies are applied (4),
including the thermal treatment of donated milk. This treatment is known as pasteurization and
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is defined as the process of heating a food, usually a liquid, at a
specific temperature during a predefined period of time and then
immediately cooling it after it is removed from the heat.
Human milk is a complex mixture of essential nutrients and
bioactive molecules designed not only to cover the nutritional
needs of the neonate but also to facilitate the process of
maturation of various organs as gut and brain (5). From a
nutritional standpoint, this heat-treatment does not seem to
affect the macronutrient composition (protein, carbohydrates
and lipids, including polyunsaturated fatty acids) of milk.
However, there are many evidences showing that there is a
drastic decrease in lipase activity, as well as a substantial drop
in the concentrations of various biological factors such as IgA,
lactoferrin, lysozyme, cytokines and growth factors (6, 7). Thus,
in the process of securing human milk, there is a decrease of milk
quality due to the destruction of some biological components.
The literature shows the enormous importance that the biological
factors present in milk represent for the development and
maturation of the newborn (8, 9). That is why one of the goals
of milk banks must be to process human milk trying to damage
these factors as little as possible during processing.
Although the trend toward a better preservation of biological
factors is focused through the development of new treatments
(10, 11), such as High Temperature Short Time (HTST)
(12, 13), High pressure processing (HPP) (14) or Ultraviolet
(UV) irradiation (15), there is a difficulty to transfer into
practice, given the lack of appropriately scaled and economically
affordable equipment to be used in milk banks. A simpler and
alternative approach would be to optimize the conventional
pasteurization technique in such a way that, maintaining the
destructive capacity on infectious elements, it retains as much
as possible the biological components of human milk. This
option has the advantage that it would allow to reuse the
pasteurization equipment currently available in most milk banks,
without needing to acquire new equipment, simply by adjusting
the temperature.
There are clear evidences that temperatures lower than
those recommended nowadays (Holder pasteurization; 30min
at 62.5◦C) are less deleterious with the biological components
of milk, whereas, retaining the capacity to destroy bacterial and
viral [HIV, HTLV-I, Polioviruses, Chikungunya Virus (CHIKV),
West Nile Virus (WNV)] contaminations in donor human milk
(16, 17). Unfortunately, there are few data about the sensitivity of
Human Cytomegalovirus (HCMV) to the range of temperatures
between 56 and 63◦C. In a recent paper (18) Maschmann et
al., concluded that temperatures above 60◦C for performing
short-term pasteurization are enough for the purpose of CMV
inactivation. However, they used a short-term heating protocol
done with a prototype of a commercially available machine
(Virex, Klaus Lauf, Germany) and aliquots of 20ml of breast
milk, instead of the conventional equipment (pasteurizer) and the
conventional volumes (50–250ml) of a human milk bank.
Therefore, the aim of this work has been to evaluate the
temperature sensitivity of HCMV during the processing of donor
breast milk under the same conditions that are commonly used
in human milk banks. If it is confirmed that HCMV is destroyed
at temperatures lower than that used in Holder pasteurization,
as shown in the literature for most infectious agents (16, 17),
the possibility of a thermal treatment of donated milk more
respectful with its biological components would be possible and
this would be beneficial for the receptors.
MATERIALS AND METHODS
Milk Samples
Human milk samples were obtained from the Human Milk Bank
of the Città della Salute e della Scienza of Turin, Italy, in 2018. The
study has been reviewed and approved by the Ethics Committee
of Italian Association of Human Milk Banks (Milan, Italy) 1
month before the beginning. The donors cleaned their hands
and breasts according to the Italian HMB guidelines. The milk
specimens were collected in sterile bisphenol-free polypropylene
bottles using a breast pump and stored at−20◦C until processed.
The specimens were thawed overnight in refrigerated conditions
and then processed according to the appropriate technique.
Cells
Human Foreskin Fibroblasts (HFF-1) (ATCC SCRC-1041) at
low-passage-number (<30) were grown as monolayers in
Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, St. Louis,
MO, USA) supplemented with 10% fetal calf serum (FCS)
(Sigma), 1mM sodium pyruvate and 1% antibiotic-antimycotic
solution (Zell Shield, Minerva Biolabs, Berlin, Germany).
Virus
A (BAC)-derived HCMV strain Towne, incorporating the
GFP sequence was propagated on HFF-1s. The GFP marker
facilitates identification of infected eukaryotic cells (19). Human
cytomegalovirus strain AD169 was purchased from the ATCC
(VR-538). Viral stocks were prepared by infecting HFF-1s at a
virus-to-cell ratio of 0.01. The cells were incubated in DMEM
supplemented with 2% heat-inactivated FCS and cultured until a
marked cytopathic effect was observed. Stocks were centrifugally
clarified and frozen at −80◦C. Virus titers were determined by
fluorescent focus assay for strain Towne andHCMVAD169 titers
were determined on HFF-1 cells using the median tissue culture
infective dose (TCID50) method.
Virus Spiking Experiments
Raw milk samples from the mothers were spiked with an
inoculum of HCMV strain Towne of 50,000 foci forming units
(FFU) in 100 µl of milk for PCR-thermocycler experiments and
in 1ml of milk for “disposable baby bottles” experiments. Two
inocula of 104 and 3× 105 TCID50 were used in 1ml of milk for
“disposable baby bottles” experiments for HCMV strain AD169.
Final volumes of milk were 100µl for pasteurization experiments
performed in a PCR-thermocycler and 130ml in baby bottles
incubated in water bath.
Pasteurization
Preliminary experiments were performed in a PCR-thermocycler
(C1000 Thermal Cycler, Bio-Rad). In a first study, each 100
µl of HCMV-Towne-spiked milk specimens were incubated for
30min at different temperatures (48–63◦C) and then cooled at
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4◦C. An additional sample of spiked milk was incubated for
30min at 4◦C as a control. The virus-milk mixtures were then
diluted in cell culture medium (1:2) and added to pre-plated cells
to test virus infectivity, as described below. In a second study, a
time-kinetics of heat treatment was carried out for 30, 20, 10, 5,
2, and 1min at different temperatures (48–63◦C).
Then, pasteurization experiments were performed in
disposable baby bottles incubated in a water bath, a procedure
resembling common pasteurization practice currently in use
in human donor milk banks for milk pasteurization. In this
case, 1ml HCMV-spiked milk in dialysis membrane tubing
was inserted in disposable milk storage baby bottles containing
130ml of milk. For each experiment, a control included 1ml of
milk challenged with constant amount of HCMV and kept at
4◦C for 30min. All experiments were performed in duplicate.
After thermal treatment, the residual HCMV-challenged milk
was collected, and the HCMV infectivity assay was performed as
described below.
HCMV Infectivity Assay
HFF-1 cells were seeded in 96-well plates at a density of 5 × 103
cells/well and incubated at 37◦C in a 5% CO2 atmosphere for
24 h. Cells were infected with a 1:2 dilution of the pasteurized
spiked milk in DMEM supplemented with 2% of heat-inactivated
FBS for 2 h at 37◦C. Then monolayers were washed five times
and incubated with 1.2%-methylcellulose DMEM medium with
2% FBS. HCMV-Towne-infected cells were visualized as green
fibroblasts on a confocal fluorescence microscope (LSM510, Carl
Zeiss, Germany) and counted 5 days post-infection. After 5
or 10 days of incubation, HCMV-AD169-infected cells were
fixed and subjected to HCMV specific immunostaining using an
anti-HCMV IEA monoclonal antibody (11-003; Argene, France)
and an UltraTech HRP streptavidin–biotin detection system
(Beckman Coulter, France), in order to detect the viral IEA
protein expression (20). All the experiments were performed
in triplicate.
Cell Viability Assay
Cell viability was assessed using the 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium assay as described previously (21). The effect
of breast milk dilutions on cell viability was expressed as a
percentage of absorbance values of treated cells compared with
those of cells incubated with culture medium alone. The 50%-
cytotoxic dilutions (CD50) and 95% confidence intervals were
determined with Prism 4 software (GraphPad Software, USA).
RESULTS AND DISCUSSION
Effect of Different Time-Temperature
Combinations on HCMV Infectivity
To determine the effectiveness of different time-temperature
combinations of pasteurization on HCMV infectivity in human
milk, raw milk samples from donor mothers were spiked
with an inoculum of GFP-expressing HCMV-Towne. The
inoculated milk was then heat-treated in the range 48–63◦C
for 1, 2, 5, 10, 20, and 30min in a PCR-thermocycler or
kept at 4◦C. Diluted samples were then analyzed by HCMV
infectivity assays on inoculated cell monolayers and examined
for GFP expression by fluorescence microscopy, as described in
Supplementary Figure 1A.
The time-kinetics study of HCMV inactivation at different
degrees revealed that no signs of HCMV replication were
observed in treatments at temperatures≥60◦C for 1min, at 59◦C
for 2min, in the range from 54 to 58◦C for 5min, and at 53◦C for
10min (Supplementary Figure 1B). By contrast, the exposition
to 52, 51, 50, 49, and 48◦C resulted in a temperature-dependent
reduction of infectivity without the total elimination of infected
cells in the considered range of time.
Supplementary Figure 1C shows that a high number of
GFP-expressing cells are visible in monolayers infected with
only viruses maintained at 4◦C for 30min as positive control
(control virus). Instead, a reduced number of green cells was
reported when virus was incubated with milk at 4◦C for 30min
(control milk plus virus) due to the antiviral properties of
human breast milk, as we published recently (22). By contrast,
the viral infectivity was completely abolished, and no GFP-
expressing cells could be detected in cell monolayers infected
with pasteurized HCMV-spiked milk at temperatures and times
before mentioned (Milk plus virus). Preliminary experiments
were conducted to determine whether the 1:2 dilution of the
pasteurized spiked milk, used in the viral assays, was toxic on
cells. No impact of the diluted milk sample on cell viability was
observed (data not shown).
According to the literature, long time pasteurizations for
30min at temperatures lower than 62.5◦Cwere effective to inhibit
most of viruses. In fact, CHIKV and WNV are inactivated at
58◦C for 30min, Polioviruses at 55◦C for 30min, HTLV-I at
56◦C for 30min, HCV at 60◦C for 30min and HIV at 60◦C at
a time <30min (23–27). Indeed, 30min can be considered the
optimal time for a broad inactivation of breast milk-transmitted
viruses. For these reasons, further studies of pasteurization were
performed at this time.
Investigation of the Effect of Different
Temperatures on HCMV Replication in a
Pasteurizer-Like Model
In order to investigate the effect of different pasteurization
temperatures on HCMV infectivity in a pasteurizer-like
model, a constant amount of HCMV strain-Towne was
challenged in 1ml milk in dialysis membrane bags inserted
in disposable milk storage baby bottles containing 130ml of
milk. The bottles underwent heating treatment for 30min
at 56, 57, 58, 59, and 60◦C and then, the whole spiked
milk, recovered from the dialysis membrane bags, was
inoculated on HFF-1 cell monolayers for the detection of
viral infectivity examining the GFP expression as previously
described (Supplementary Figure 2A). The thermal profiles
of pasteurizations are reported in Supplementary Figure 3.
As reported in Supplementary Figures 2B,C, HCMV was
inactivated by any tested time-temperature combination,
whereas, all the wells of controls exhibited clear signs of HCMV
infection. The average number of FFU/ml was 2050 in the
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control milk plus virus (at 4◦C for 30min), and uncountable for
the control virus (at 4◦C for 30min). These data confirm that
the thermal treatments at 60, 59, 58, 57, and 56◦C for 30min
inactivated HCMV completely in our model system.
To validate our results at 60◦C, the assay was performed in
the pasteurizer-like model with a different laboratory HCMV
strain, AD169, used as model in pasteurized HCMV inactivation
assays (28). Spiking of the breast milk samples was done by
adding two viral inocula (104 and 3 × 105 TCID50 per milliliter
of milk) and the viral infectivity was assessed by an indirect
immunoperoxidase staining procedure at 5 and 10 days post
infection (dpi) (Figure 1A). At 5 dpi, the read-out of the viral
infectivity was the number of infected cells or foci, brown stained
by the immediate early antigen (IEA) staining/ per milliliter
milk (Figure 1D). As reported in Figure 1B, a total inhibition of
viral infectivity was observed at 60◦C for 30min at 5 days post
infection for both viral inocula. The concentration of virus in the
different inocula is much higher than what is detected in any wild
type infected breast milk (18). At 10 dpi, brown foci or plaques,
generated by the cell-to-cell viral spread, were detected in the
control, and again a total absence of detectable cytopathic effect
was obtained at 60◦C for 30min (Figures 1C,E).
Today the Holder pasteurization (30min at 62.5◦C) is still
considered as “gold standard” to avoid transmission of pathogens
to breastfed infants. However, its harmful effects on nutritional
and immunological components of breast milk have induced the
study of different ways of HCMV inactivation (10). Bapistella
et al. (29) assessed the effectiveness of short-term pasteurization
(62◦C for 5 s) in preventing HCMV transmission via breast
milk observing a reduction in the proportion of HCMV
transmission from 20.5 to 2.3% preterm infants. Recently, HTST
pasteurization has been reported to be a valuable alternative
technology to increase the retention of some biological features,
like the antiviral properties of human milk (30). Klotz et al. (28)
evaluated the antiviral and antibacterial efficacy of different time-
temperature combinations of HTST observing that the treatment
inactivatedHCMVbut is less effective thanHolder pasteurization
in bacterial count reduction. A new short-term heat treatment
subjecting samples for 5 s to different temperatures (55–72◦C)
has been recently studied for its impact on HCMV inactivation
(18). However, this is a very small-scale technique, not useful to
be used in conventional HMB to process liters of human milk.
Herein, we evaluated preliminarily the impact of different
temperature-time combinations on HCMV infectivity in a PCR-
thermocycler. Analyzing the exposition of virus-spiked milk
between 48 and 63◦C, our experiments showed that the rate of
HCMV inactivation was 100% at temperatures equal or >60◦C
for 1min, whereas, lower temperatures gradually diminished
the efficacy and required a longer time to totally inhibit
the infectivity. Our experiments in a pasteurizer-like model
confirmed the complete HCMV inactivation treating virus-
spikedmilk for 30min in the range from 56 to 60◦C and validated
the efficacy of the pasteurization at 60◦C for 30min against two
laboratory HCMV strains.
As regards thermo-sensitivity in bacteria, few studies have
focused on the susceptibility of the microbial strains. The most
complete study addressing this issue was published by Czank
et al. (31). They observed that incubating human milk, spiked
with different bacterial species, at 57◦C for 30min was enough
to reduce all bacterial species tested by 99.9%. The authors
conclude that the current practice, Holder pasteurization, may
be considered as excessive for pasteurizing human milk donated
to the milk banks. This overheating is probably explained, as
we discussed in a previous paper (16), because the temperature
chosen to pasteurize in the human milk banks, 62.5◦C for
30min, comes from data obtained with cow’s milk in dairy
industry and not from a systematic analysis using human milk.
It should be noted that the analysis was done by using an
experimental pasteurizer, designed specifically for that study
and not in the conventional conditions of a human milk bank.
Working in these conventional conditions, we have obtained
preliminary data (Calvo et al., manuscript in preparation)
confirming that, by pasteurizing at 60◦C, the flora usually
present in the milk samples received at our milk bank is
completely destroyed. The exception is Bacillus spp, that, as it
is well-known, has the ability to resist pasteurization due to
its sporulation capacity (32). In fact, Bacillus cereus has been
described as the primary cause of rejection for pasteurized human
milk (33, 34).
We consider that our results are especially relevant in order
to protect the biological factors present in human milk, as it has
been described by Czank et al. (31) that the temperature and
not the holding time, is the critical element for the retention
of IgA, lysozyme and lactoferrin, with significant differences
in the retention of these three proteins by modifying the
temperature of treatment just by 1◦C. These data, however,
were obtained by using a specially designed pasteurizer, different
than those commonly used in human milk banks. For that
reason, we have started a project to analyze the effect of different
temperatures on some biological factors, after the heat treatment
of human milk using the conventional conditions used in human
milk banks.
In conclusion, our data clearly confirm that the heat
treatment for 30min at 60◦C guarantees the total inactivation
of HCMV. Taking into account that previous reports suggest
that this is also applicable to other breastfeeding transmitted
viruses, like HIV, HTLV and Parvovirus B19 (16, 17), we
consider that this variant of Holder pasteurization may
be a good compromise between the microbial inactivation
and the preservation of nutritional properties using the
same pasteurizer equipment found in most of Human Milk
Banks. These aspects make the procedure of pasteurization
favorable especially in low-income countries. A limitation of
this study is to have performed experiments on artificially
spiked breast milk samples, infected with laboratory HCMV.
Further studies will be necessary to confirm the inactivation
of infectivity of free clinical strains and cell associated
ones in naturally CMV-infected breast milk at 60◦C for
30min. Moreover, future studies are required in relation
with the bacterial destruction and the preservation of the
biological components to definitively validate this variant
of pasteurization.
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FIGURE 1 | Effects of treatment at 60◦C for 30min on HCMV strain AD169 infectivity at two different titers in a pasteurizer-like model. (A) Heat treatment and infection
protocol for HCMV. (B,C) In the graphs, HCMV infectivity of heat-treated milk samples spiked with HCMV AD169 at two titers (1 × 104 TCID50 and 3 × 105 TCID50)
is reported as number of infected cells/ml at 5 days post infection (B) and as FFU/ml at 10 days post infection (C). (D,E). Representative figures of HFF-1 cells treated
with milk samples spiked with HCMV (3 × 105 TCID50) and treated at 4◦C for 30min (unpasteurised, left) or at 60◦C for 30min (pasteurized, right) at 5 days post
infection (D) and 10 days post infection (E). Infected cells and foci are brown by immunostaining. UP, unpasteurised.
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